Author

Yaman Tayyar

Griffith UniversityORCID 0000-0003-4385-0569Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

Nigel A.J. McMillaniD· 2 shared Adi IdrisiD· 1 shared Alicia M. DavisiD· 1 shared Andreas SuhrbieriD· 1 shared Aroon SupramaniamiD· 1 shared Bing TangiD· 1 shared Cameron BishopiD· 1 shared Christopher L. D. McMillaniD· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

Nigel A.J. McMillanORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

MicrobiologyMolecular Therapy — Nucleic AcidsPeer-reviewedDec 12, 2024

Harnessing defective interfering particles and lipid nanoparticles for effective delivery of an anti-dengue virus RNA therapy

Min‐Hsuan Lin, Pramila Maniam, Dongsheng Li…·David Harrich

This paper demonstrates that DI290-loaded lipid nanoparticles (LNP-290) effectively suppress DENV infection in cell cultures and mice, inducing IFN responses and preventing clinical signs.

6 citations

mousehuman

𝕏 PostBluesky

Synthetic BiologyMolecular TherapyPeer-reviewedMay 13, 2021

A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19

Adi Idris, Alicia M. Davis, Aroon Supramaniam…·Kevin V. Morris

This paper develops an siRNA-nanoparticle therapy targeting SARS-CoV-2 that reduces viral load and improves survival in mice.

165 citationstop 1%

humanexperimental assay

𝕏 PostBluesky